hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06342596 id: 18597 id: J2O-MC-EKBD type: OTHER domain: Eli Lilly and Company briefTitle: A Study of Carbon-14-Labelled [14C] LY3473329 in Healthy Male Participants overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-05 date: 2024-04 date: 2024-04 date: 2024-04-02 date: 2024-04-19 name: Eli Lilly and Company class: INDUSTRY briefSummary: The main purpose of this study is to evaluate how much of the study drug (LY3473329), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air in healthy male participants. The study will also measure how much of the study drug gets into the bloodstream when taken orally, compared to when injected directly into the vein, how its broken down, and how long it takes the body to get rid of it. The study is conducted in two parts. The study will last up to approximately 9 and 7 weeks for part 1 and 2, respectively. conditions: Healthy studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SEQUENTIAL primaryPurpose: BASIC_SCIENCE masking: NONE count: 16 type: ESTIMATED name: [14C]-LY3473329 name: [14C]-LY3473329 name: LY3473329 measure: Part 1: Urinary Excretion of LY3473329 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered measure: Part 1: Fecal Excretion of LY3473329 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered measure: Part 2: Pharmacokinetics (PK): Absolute bioavailability (F) of LY3473329 measure: Part 1: PK: Area Under the Curve Concentration Versus Time Curve From Time zero to Last Time Point (AUC[0-tlast]) of LY3473329 measure: Part 1: PK: Area Under the Curve Concentration Versus Time Curve From Time zero to Last Time Point (AUC[0-tlast]) of Total Radioactivity measure: Part 1: PK: Area Under the Curve Concentration Versus Time Curve From Time zero to Infinity (AUC[0-∞) of LY3473329 measure: Part 1: PK: Area Under the Curve Concentration Versus Time Curve From Time zero to Infinity (AUC[0-∞) of Total Radioactivity measure: Part 1: PK: Maximum Concentration (Cmax) of LY3473329 measure: Part 1: PK: Maximum Concentration (Cmax) of Total Radioactivity measure: Part 1: Total Radioactivity Recovered in Urine, Feces, and Expired Air (if applicable) measure: Part 1: Total Number of Metabolites of LY3473329 measure: Part 2: PK: AUC (0-∞) of LY3473329 measure: Part 2: PK: AUC (0-∞) of [14C]-LY3473329 measure: Part 2: PK: AUC (0-∞) of Total Radioactivity measure: Part 2: PK: Cmax of LY3473329 measure: Part 2: PK: Cmax of [14C]-LY3473329 measure: Part 2: PK: Cmax of Total Radioactivity measure: Part 2: Total Radioactivity Recovered in Urine and Feces sex: MALE minimumAge: 35 Years maximumAge: 55 Years stdAges: ADULT facility: Fortrea Clinical Research Unit city: Holbeck state: Leeds zip: LS11 9EH country: United Kingdom lat: 53.25 lon: -1.18333 hasResults: False
nctId: NCT06342583 id: CNR-IRIB-PRO-2024-004 briefTitle: Advanced Social Relations Training overallStatus: RECRUITING date: 2024-03-01 date: 2025-03-17 date: 2026-02-10 date: 2024-04-02 date: 2024-04-02 name: Istituto per la Ricerca e l'Innovazione Biomedica class: OTHER name: Messina, Italy briefSummary: Advanced social relations protocol is aimed at young people with autism aged 9-12 years with an intelligence quotient (IQ) ≥ 80. There will be an experimental group in which technology will be used and a control group in which activities will be carried out in the traditional way. The protocol will be carried out once a week for a duration of 45 minutes. The aim is to enhance communication and social skills within the group. A total of 23 sessions are planned. From the first to the third session the participants will acquire skills for communicating and conversing in an appropriate way. Thereafter from the fourth to the eleventh session social stories illustrating scenes from everyday life will be shown, with the aim of learning and managing the dynamics in which they find themselves on a daily basis. At the end of each story shown they will be asked to impersonate the protagonists depicted in the stories, each participant involved in turn will play all the roles shown in the stories, thus working in the mode of role playing.
The last part, which includes sessions from the twelfth to the twenty-third, will be dedicated to the correct and conscious use of social networks with a focus on the risks that can be encountered and the correct ways to make good use of them. conditions: Autism conditions: Autism Spectrum Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 30 type: ESTIMATED name: Advanced social relations training with technical device name: Advanced social relations training without technical device measure: Vineland-II (Vineland Adaptive Behavior Scales-II - Survey Intervention Form) measure: Eye contact measure: Smile in relation to group members' expressions measure: Greeting measure: Asking a question measure: Proposing an idea or activity to be carried out measure: Answering a question measure: Taking verbal initiative measure: Approval/sharing gestures sex: ALL minimumAge: 9 Years maximumAge: 12 Years stdAges: CHILD facility: Institute for Biomedical Research and Innovation (IRIB) - National Research Council (CNR) status: RECRUITING city: Messina zip: 98164 country: Italy name: Flavia Marino role: CONTACT phone: +393395798263 email: flavia.marino@irib.cnr.it name: Maria Valeria Maiorana role: CONTACT phone: +393285856656 email: mariavaleria.maiorana@irib.cnr.it name: Flavia Marino role: PRINCIPAL_INVESTIGATOR name: Giovanni Pioggia role: SUB_INVESTIGATOR name: Paola Chilà role: SUB_INVESTIGATOR name: Roberta Minutoli role: SUB_INVESTIGATOR name: Noemi Vetrano role: SUB_INVESTIGATOR name: Chiara Failla role: SUB_INVESTIGATOR name: Germana Doria role: SUB_INVESTIGATOR name: Ileana Scarcella role: SUB_INVESTIGATOR name: Cinzia Grasso role: SUB_INVESTIGATOR name: Mariaelena Franchina role: SUB_INVESTIGATOR lat: 38.19394 lon: 15.55256 hasResults: False
nctId: NCT06342570 id: 3-2023-0462 briefTitle: Quantitative Analysis of EEG Changes in Response to Nociception overallStatus: RECRUITING date: 2024-04-18 date: 2026-12-30 date: 2026-12-30 date: 2024-04-02 date: 2024-04-17 name: Gangnam Severance Hospital class: OTHER briefSummary: This study will quantify the nociception using Analgesia Nociception Index (ANI) during general anesthesia and analyze the differences in EEG depending on the degree of nociception. Additionally, the investigators will quantify the nociception during recovery and analyze the differences in EEG depending on the degree of nociception. conditions: Patients Undergoing Laparoscopic Surgery studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 109 type: ESTIMATED name: There is no Intervention name to describe. measure: Correlation between changes in ANI and EEG band power in response to surgical stimulation. measure: Correlation between changes in ANI and EEG band power in response to tracheal intubation measure: Correlation between changes in ANI and EEG connectivity in response to surgical stimulation measure: Correlation between changes in ANI and EEG connectivity in response to tracheal intubation measure: Correlation between changes in ANI, EEG band power and NRS in response to analgesic administration measure: Correlation between changes in ANI, EEG connectivity and NRS in response to analgesic administration measure: Differences in EEG band power(Delta, Theta, Alpha, Beta, Gamma) during surgery between groups with large and small changes in ANI measure: Differences in EEG connectivity during surgery between groups with large and small changes in ANI measure: Differences in EEG band power(Delta, Theta, Alpha, Beta, Gamma) during recovery between groups with large and small changes in ANI measure: Differences in EEG connectivity during recovery between groups with large and small changes in ANI measure: Differences in EEG band power(Delta, Theta, Alpha, Beta, Gamma) depending on the type of inhaled anesthetic measure: Differences in EEG connectivity depending on the type of inhaled anesthetic measure: Differences in ANI depending on the type of inhaled anesthetic sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: GangnamSeverance Hospital status: RECRUITING city: Seoul country: Korea, Republic of name: Myung Il Bae role: CONTACT phone: 82-2-2019-6611 email: BMI87@yuhs.ac lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06342557 id: FROM briefTitle: Transitional ePRO Diary Liver acronym: MACROLIVER overallStatus: RECRUITING date: 2024-03-28 date: 2034-02-21 date: 2034-02-21 date: 2024-04-02 date: 2024-04-16 name: FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS class: OTHER briefSummary: The study is part of the MACROLIVER Project, whose main objective is to create a digital tool for patients and caregivers for the management of liver disease that allows the optimization of therapy and/or the treatment process, even remotely. Such a tool not only reduces the movement of patients who are by definition fragile, but also enables the optimization of access and care by a multidisciplinary team. This tool is intended to support doctors and patients, but in no way replaces normal clinical practice. This study aims to explore the specificities of patients experiencing the transition from the pediatric ward to the adult ward in order to identify risk and protective factors that influence psychological well-being at both an individual and relational level. In order to gather all the information about the patients attending the transitional clinic and to obtain a more complete and truthful clinical-psychological picture, the study also includes the collection of retrospective data of the transplanted patients. conditions: Liver Transplant studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 250 type: ESTIMATED measure: four-item Morisky Medication Adherence Scale (MGLS) sex: ALL minimumAge: 14 Years maximumAge: 20 Years stdAges: CHILD stdAges: ADULT facility: ASST-Papa Giovanni XXIII status: RECRUITING city: Bergamo state: Milano zip: 24127 country: Italy name: Stefano Fagiuoli, MD role: CONTACT phone: 035.2674259 email: sfagiuoli@asst-pg23.it lat: 45.69601 lon: 9.66721 hasResults: False
nctId: NCT06342544 id: AGN_2023_14 briefTitle: Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial. acronym: IMCOMG overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2028-06 date: 2029-06 date: 2024-04-02 date: 2024-04-02 name: Fondation Ophtalmologique Adolphe de Rothschild class: NETWORK briefSummary: Myasthenia is an autoimmune disease causing dysfunction of the neuromuscular junction, resulting in fluctuating and variable muscle weakness.
In the initial phase of the disease, 70% of patients present with ocular onset myasthenia (OMG), i.e. weakness limited to the oculomotor muscles. Generalization to skeletal, bulbar and axial muscles occurs in 20-40% of cases, with a higher frequency in the first and second years, respectively 46% and 60% of generalizations. This reflects the maturation of the autoimmune response in the early years of the disease, and represents a therapeutic window of opportunity to modify the course of the disease.
Patients with ocular myasthenia are usually treated symptomatically with acetylcholinesterase inhibitors. The introduction of corticosteroids is delayed and limited to patients with persistent disabling diplopia or ptosis with occlusion. When corticosteroids are tapered off, ocular symptoms may recur. This level of corticosteroid dependence observed in patients treated for ocular myasthenia has not been specifically studied. In order to reduce the levels of corticosteroids administered and avoid recurrence of ocular symptoms and their delayed generalization, it is usually proposed to introduce another immunosuppressant.
The aim of this study is to evaluate the efficacy of a standardized proactive prevention strategy on the generalization of ocular onset myasthenias during the first 2 years. It will combine immediate treatment with corticosteroids at the time of diagnosis, with the addition of rituximab in the event of recurrence of ocular symptoms as corticosteroids are tapered off. conditions: Ocular Myasthenia Gravis studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 128 type: ESTIMATED name: immediate treatment with corticosteroids name: addition of rituximab if recurrence measure: proportion of patients who progressed to generalized myasthenia within 2 years of follow-up sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06342531 id: 210324 briefTitle: More Effective Violence Risk Management - eDASA+APP FI acronym: eDASA+APP FI overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-12 date: 2026-12 date: 2024-04-02 date: 2024-04-02 name: University of Turku class: OTHER name: Helsinki University Central Hospital briefSummary: The main goal of this study is to evaluate if the Finnish version of eDASA+APP (electronic Dynamic Appraisal of Situational Aggression + Aggression Prevention Protocol), a clinical decision support system (CDSS), has an impact on reducing workplace violence, use of coercive measures and increasing nurses' job satisfaction in adult psychiatric inpatient care. conditions: Violence studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: A pre-post design (quasi-experimental), a cluster design primaryPurpose: SCREENING masking: NONE count: 26 type: ESTIMATED name: eDASA+APP FI measure: Workplace violence measure: Coercive measures measure: Job satisfaction sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06342518 id: MU ESWT briefTitle: ESWT in Lateral Epicondylitis: Clinical,Ultrasonographic Evaluation overallStatus: COMPLETED date: 2020-12-01 date: 2021-09-01 date: 2021-12-01 date: 2024-04-02 date: 2024-04-02 name: Istanbul Medeniyet University class: OTHER briefSummary: This study aimed to check and compare how well shock wave therapy works for tennis elbow, both in terms of symptoms and what we can see on ultrasound. conditions: Lateral Epicondylitis conditions: Tennis Elbow studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 42 type: ACTUAL name: Extracorporeal Shock Wave Therapy (ESWT) name: Sham ESWT name: Resting Splint , Exercises and ice measure: Hand Grip Strength measure: Pain severity measure: Functionality measure: Quality of life score measure: deep muscular tissue sensitivity measure: thickness of the common extensor tendon (CET) sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Istanbul Medeniyet University Faculty of Medicine, Physical Medicine and Rehabilitation Department city: Istanbul zip: 34732 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06342505 id: MEC-2022-0037 briefTitle: Tacrolimus in CD3+ T Lymphocytes acronym: INTACT overallStatus: COMPLETED date: 2022-05-30 date: 2022-10-10 date: 2022-11-10 date: 2024-04-02 date: 2024-04-02 name: Erasmus Medical Center class: OTHER briefSummary: The goal of this study is to measure concentrations of the drug tacrolimus in both whole blood and within T lymphocytes. It will also learn on the correlation between the concentration in T lymphocytes and the effects of the drug. The main questions are:
* Undergo two extra venipunctures for the collection of blood. conditions: Immunosuppression studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 28 type: ACTUAL name: Venipunctures measure: The intracellular tacrolimus concentration in CD3+ T lymphocytes measure: Intracellular cytokine production sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erasmus MC city: Rotterdam zip: 3015 GD country: Netherlands lat: 51.9225 lon: 4.47917 hasResults: False
nctId: NCT06342492 id: KCHRRF_CS Lead Failure_0025 briefTitle: Conduction System Vs Surgical Left Ventricular Epicardial Pacing For Coronary Sinus Lead Failure overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-10 date: 2024-12 date: 2024-04-02 date: 2024-04-02 name: Kansas City Heart Rhythm Research Foundation class: OTHER briefSummary: This a single-center, retrospective, observational study of patients that undergo coronary sinus(CS) lead revision, comparing epicardial lead placement to coronary sinus pacing(CSP) in those that had lead failure. conditions: Heart Failure With Reduced Ejection Fraction studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 100 type: ESTIMATED name: Coronary Sinus Lead Revision measure: Need for lead revision measure: Electrocardiography characteristics - QRS Interval sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Menorah Medical Center city: Overland Park state: Kansas zip: 66209 country: United States lat: 38.98223 lon: -94.67079 facility: Kansas City Heart Rhythm Institute - Roe Clinic city: Overland Park state: Kansas zip: 66211 country: United States lat: 38.98223 lon: -94.67079 facility: Overland Park Regional Medical Center city: Overland Park state: Kansas zip: 66215 country: United States lat: 38.98223 lon: -94.67079 facility: Centerpoint Medical Center Clinic city: Independence state: Missouri zip: 64057 country: United States lat: 39.09112 lon: -94.41551 facility: Centerpoint Medical Center city: Independence state: Missouri zip: 64057 country: United States lat: 39.09112 lon: -94.41551 facility: Research Medical Center Clinic city: Kansas City state: Missouri zip: 64032 country: United States lat: 39.09973 lon: -94.57857 facility: Research Medical Center city: Kansas City state: Missouri zip: 64032 country: United States lat: 39.09973 lon: -94.57857 hasResults: False
nctId: NCT06342479 id: NM: 04.20.ND:30.03.2023 briefTitle: Discharge Training for Patients With Intertrochanteric Fracture overallStatus: RECRUITING date: 2023-09-01 date: 2024-06-01 date: 2024-07-01 date: 2024-04-02 date: 2024-04-02 name: Erzurum Technical University class: OTHER briefSummary: This study examines the effect of discharge training given to patients with intertrochanteric femur fractures on the wound healing process and readiness for discharge. In the study, patients were provided with certain educational content before and after discharge. The effect of training on wound healing, readiness for discharge and post-discharge recovery process will be evaluated statistically. conditions: Surgical Wound studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Discharge Education measure: Toronto Wound Symptom Assessment System measure: Discharge readiness scale sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erzurum Technical University Faculty of Health Sciences status: RECRUITING city: Erzurum zip: 25000 country: Turkey name: Yasemin Erden role: CONTACT phone: 05303461516 email: yasemin.erden@erzurum.edu.tr lat: 39.90861 lon: 41.27694 hasResults: False
nctId: NCT06342466 id: 2023-358-02 briefTitle: Bortezomib, Pomalidomide, Dexamethasone For Systemic AL Amyloidosis overallStatus: RECRUITING date: 2024-04 date: 2026-12 date: 2026-12 date: 2024-04-02 date: 2024-04-02 name: Jin Lu, MD class: OTHER briefSummary: This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed systemic light chain (AL) amyloidosis. Approximately 40 subjects will receive therapy with bortezomib, pomalidomide, and dexamethasone. The primary outcome is hematologic very good partial response and complete response rate at 6 months. conditions: Systemic Amyloidosis studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Bortezomib, pomalidomide, dexamethasone primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Bortezomib name: Pomalidomide name: Dexamethasone measure: Hematologic VGPR + CR rate at 6 months measure: Overall Hematologic response rate at 6 months measure: At least one organ response at 6 months measure: TTNT at 2 years measure: Estimated PFS at 2 years measure: Estimated OS at 2 years measure: TRAE sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking University People's Hospital status: RECRUITING city: Beijing state: Beijing zip: 100044 country: China name: Yang Liu role: CONTACT phone: +8613716926210 email: pkuphliuyang@bjmu.edu.cn name: Jin Lu role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06342453 id: STUDY00026814 id: NCI-2024-01534 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: STUDY00026814 type: OTHER domain: OHSU Knight Cancer Institute briefTitle: Examining Arts as Therapy in Children With Cancer, CREATe Trial overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-03-30 date: 2026-03-30 date: 2024-04-02 date: 2024-04-02 name: OHSU Knight Cancer Institute class: OTHER name: Oregon Health and Science University name: National Center for Complementary and Integrative Health (NCCIH) briefSummary: This clinical trial is being done to develop and test how well creative arts interventions (drawing, painting, making sculptures) compared to watching videos can affect symptoms and impact the quality of life in children with cancer. Creative arts mind-body interventions (CrA) are one type of complementary health interventions which have been associated with improved quality of life and reduced symptom burden among children with cancer. CrA is an ideal intervention for children with cancer due to the long hours spent in the hospital setting for treatments, the creativity and developmental focus of children, and their potential ability to communicate more easily through art than words. Researchers want to develop and test a CrA intervention to help improve symptoms and the quality of life of children with cancer. conditions: Hematopoietic and Lymphatic System Neoplasm conditions: Malignant Solid Neoplasm studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 72 type: ESTIMATED name: Art Therapy name: Discussion name: Media Intervention name: Survey Administration measure: Number of participants that complete all interventions and data collection time points measure: Number of eligible participants that enroll in the study (feasibility threshold of 60%) measure: Number of participants that complete all interventions and all surveys in the study. measure: Number of intervenor fidelity surveys that obtain at least 95% score. measure: Comparison of scores on the PRO-CTCAE between intervention arms measure: Comparison of scores on the PROMIS between intervention arms measure: Comparison of scores on the Faces between intervention arms sex: ALL minimumAge: 8 Years maximumAge: 13 Years stdAges: CHILD facility: OHSU Knight Cancer Institute city: Portland state: Oregon zip: 97239 country: United States name: Jennifer L. Raybin role: CONTACT phone: 503-418-5150 email: raybin@ohsu.edu name: Jennifer L. Raybin role: PRINCIPAL_INVESTIGATOR lat: 45.52345 lon: -122.67621 hasResults: False